

Article

Sex-based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy - a Retrospective Bi-Centric Cohort Study

David Lang^{1*}, Anna Brauner², Florian Huemer³, Gabriel Rinnerthaler³, Andreas Horner¹, Romana Wass¹, Elmar Brehm¹, Bernhard Kaiser¹, Richard Greil³, Bernd Lamprecht¹

- 1) Johannes Kepler University Hospital Linz, Department of Pulmonology
Altenberger Strasse 69, 4040 Linz and Krankenhausstrasse 9, 4020 Linz,
Austria
lunge@kepleruniklinikum.at
- 2) Johannes Kepler University Linz, Medical Faculty
Altenberger Strasse 69, 4020 Linz, Austria
zkf@jku.at
- 3) Department of Internal Medicine III with Haematology, Medical Oncology,
Haemostaseology, Infectiology and Rheumatology, Oncologic Center,
Salzburg Cancer Research Institute - Laboratory for Immunological and
Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University,
Salzburg, Austria, Salzburg Cancer Research Institute-CCCIT, Cancer Cluster
Salzburg, Austria
Muellner Hauptstrasse 48, 5020 Salzburg, Austria
onkologie.salzburg@salk.at

*Corresponding author:

Dr. David Lang, Ph.D.

Department of Pulmonology, Johannes Kepler University Hospital, MedCampus III.

Krankenhausstraße 9, 4020 Linz, Austria

T: +43 5 7680 83 73797, F: +43 5 7680 83 6915

david.lang@kepleruniklinikum.at

Simple Summary

Retrospective analyses suggest that men treated with immune-checkpoint inhibitor (ICI) monotherapy for non-small cell lung cancer (NSCLC) have better outcomes than women. Female patients however have more favorable responses when chemotherapy (CHT) is given together with ICI. We aimed to explore the clinical impact of such sex differences in two cohorts, receiving ICI monotherapy or ICI-CHT combination, respectively. We found no significant difference in outcomes between men and women treated with either therapeutic regimen. However, known predictive factors for ICI response like the expression of programmed-death ligand 1 (PD-L1) on tumor cells or patient performance status had significant implications rather for men than for women. Our results warrant increased research efforts to clarify sex-specific differences in anti-tumor immune response mechanisms and in the efficacy of ICI therapies especially in women.

Abstract

Men with non-small cell lung cancer (NSCLC) have a more favorable response to immune-checkpoint inhibitor (ICI) monotherapy, while women especially benefit from ICI-chemotherapy (CHT) combinations.

To elucidate such sex differences in clinical practice, we retrospectively analyzed two cohorts treated with either ICI monotherapy (n=228) or ICI-CHT combination treatment (n=80) for advanced NSCLC. Kaplan-Meier analyses were used to calculate progression-free (PFS) and overall survival (OS), influencing variables were evaluated using Cox-regression analyses.

No significant sex differences for PFS/OS could be detected in either cohort. Men receiving ICI monotherapy had a statistically significant independent impact on PFS by Eastern Cooperative Oncology Group performance status (ECOG) ≥ 2 (hazard ratio (HR) 1.90, 95% confidence interval (CI): 1.10-3.29, $p=0.021$), higher C-reactive protein (CRP; HR 1.06, 95%CI: 1.00-1.11, $p=0.037$) and negative programmed death-ligand 1 (PD-L1) status (HR 2.04, 95%CI: 1.32-3.15, $p=0.001$), and on OS by CRP (HR 1.09, 95%CI: 1.03-1.14, $p=0.002$). In men on ICI-CHT combinations, multivariate analyses (MVA) revealed squamous histology (HR 4.00, 95%CI: 1.41-11.2, $p=0.009$) significant for PFS; ECOG ≥ 2 (HR 5.58, 95%CI: 1.88-16.5, $p=0.002$) and CRP (HR 1.19, 95%CI: 1.06-1.32, $p=0.002$) for OS. Among women undergoing ICI monotherapy, no variable proved significant for PFS, ECOG ≥ 2 had a significant interaction with OS (HR 1.90, 95%CI 1.04-3.46, $p=0.037$). Women treated with ICI-CHT had significant MVA findings for CRP with both PFS (HR 1.09, 95%CI: 1.02-1.16, $p=0.007$) and OS (HR 1.11, 95%CI: 1.03-1.19, $p=0.004$).

Although men and women responded similarly to both ICI mono- and ICI-CHT treatment, predictors of response differed by sex.

Keywords

Immunotherapy, immune-checkpoint inhibitor, response prediction, men and women, pembrolizumab, nivolumab, atezolizumab, ECOG, CRP, chemo-immunotherapy

1. Introduction

Cancer immunotherapy using immune-checkpoint inhibitors (ICI) directed against programmed death-ligand 1 (PD-L1) or programmed cell death protein 1 (PD-1) has revolutionized lung cancer treatment.[1] Originally established as monotherapy for pretreated advanced non-small cell lung cancer (NSCLC) and first-line therapy in patients with high PD-L1 expression,[2–6] its fields of application have continued to expand. In stage IV disease without targetable genetic alteration and PD-L1 expression < 50%, first-line ICI-chemotherapy (CHT) combination treatment has become state-of-the art,[7–9] while the additional value of the combination of nivolumab and the Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) inhibitor ipilimumab with or without CHT is yet to be determined.[10,11]

Early phase-3 ICI monotherapy studies in NSCLC, with the exception of the OAK study for atezolizumab, showed a numerical prognostic benefit favoring men in subgroup analyses.[2–6] This finding was initially confirmed in a systematic review and meta-analysis by Conforti et al. for NSCLC as well as for melanoma.[12]

However, a subsequently published similar investigation by Wallis et al. reported no such sex difference.[13] In the ICI-CHT combination setting in NSCLC, a systematic review and meta-analyses showed a larger benefit for women as compared to men.[14] Possible explanations for these observed sex differences may be variations in the composition of the tumor microenvironment, in T-cell differentiation as well as in mechanisms of tumor immune evasion.[15]

Our study group has evaluated various biomarkers for lung cancer immunotherapy in real-life cohorts, where women repeatedly had more favorable hazard ratios for progression-free survival (PFS) and overall survival (OS) as compared to men.[16–18] Although these differences have been small and mostly non-significant, such findings seemed interesting in the light of large-scale meta-analyses demonstrating

rather the opposite. In the present study we thus aimed to evaluate whether such sex differences could be detected in our recently updated bi-centric ICI monotherapy database as well as in a cohort of ICI-CHT-treated patients. For both cohorts, we additionally intended to elucidate sex-specific differences in the prognostic relevance of various patient- or tumor-related factors.

2. Materials and Methods

The bi-centric ICI monotherapy cohort consisted of 228 retrospectively evaluated consecutive patients with advanced NSCLC that had received at least one cycle of either nivolumab, pembrolizumab or atezolizumab at the lung cancer unit of Kepler University Hospital Linz or at the Medical Oncology unit of Paracelsus Medical University Salzburg between May 2015 and December 2019. The ICI-CHT cohort comprised 80 consecutive patients treated with platinum-based doublet CHT combined with pembrolizumab or atezolizumab (plus bevacizumab) at Kepler University Hospital Linz between June 2018 and December 2019. The patient registry as well as the present evaluation have been approved by the ethics committee of the federal state of Upper-Austria (EK Nr. 1139/2019).

Patients were retrospectively followed from ICI therapy initiation on to death or censored at the date of last verified contact. Disease progression was retrospectively defined by imaging and death, as well as by reviewing the relevant medical records. Therapy could be applied beyond disease progression in selected cases of considerable clinical benefit. Also, in stage IV patients with PD-L1 expression <50% and contraindications to CHT, first-line ICI treatment could be initiated upon tumor-board decision. Therapy line was defined as treatment for non-curable (e.g. stage IV[19] or not otherwise treatable stage III) disease, whereas previous therapies in potentially curable stages were not considered. We excluded patients in clinical trials or on ICI/ICI combinations and patients, who had previously received an ICI therapy. Chemo-immunotherapy was applied according to the respective phase 3 studies, using carboplatin/pemetrexed/pembrolizumab for non-squamous and carboplatin/paclitaxel/pembrolizumab for squamous-cell carcinomas.[7,8] A minority of patients received the IMpower-150 regimen of

carboplatin/paclitaxel/atezolizumab/bevacizumab.[9] Cisplatin was not used, and ICI-CHT combination was routinely given for four cycles if tolerated. For maintenance therapy in patients having responded to ICI-CHT treatment, only the respective ICI substance but no CHT was continued. An earlier switch to maintenance mono-immunotherapy could be performed if the treating physician deemed the continuation of combination therapy inappropriate due to intolerance and/or toxicity.

Radiological response to ICI monotherapy was routinely assessed by a chest- and upper abdomen CT scan using iodinated contrast medium every 10 to 12 weeks, equaling four cycles of nivolumab or three cycles of pembrolizumab or atezolizumab. In the ICI-CHT cohort, equivalent re-staging was performed after every two cycles of combination therapy. Re-staging could be preponed due to suspected disease progression and imaging modalities like ^{18}F -FDG-PET/CT or cerebral magnetic resonance tomography could be additionally conducted according to the treating clinician's judgement.

All statistical analyses were accomplished using R (R: A Language and Environment for Statistical Computing; Version 4.1.1; <https://www.R-project.org>). Sex-specific differences in baseline characteristics were tested for statistical significance using a two-samples t-test or the Mann-Whitney-U-test for non-normally distributed variables; categorical variables were tested using the Chi-Square-Test. Kaplan-Meier-analyses were used to calculate PFS and OS in all patients as well as according to sex.

Results were expressed as median in months (95% confidence interval (CI)) unless otherwise specified. The Kaplan-Meier curves were compared statistically using the log rank test, whereas a p -value <0.05 was regarded statistically significant. Uni- and multivariate models for predictive factors of PFS and OS were accomplished using Cox-regression analyses. Variables analyzed in these models were age (years), sex, smoking status ($<$ vs. ≥ 5 pack years), histological subtype (adeno- vs. squamous-cell

carcinoma), palliative therapy line (1,2 vs. ≥ 3), Eastern Cooperative Oncology Group performance status (ECOG; 0,1 vs. ≥ 2) and presence of a targetable genetic tumor alteration (anaplastic lymphoma kinase (ALK), epidermal growth factor receptor (EGFR), proto-oncogene tyrosine-protein kinase ROS (ROS-1)). C-reactive protein was assessed using a Cobas® 8000 modular analyzer (Roche Diagnostics International AG, Rotkreuz, Switzerland), lymphocyte count by a Sysmex® XN-3000 hematology analyzer (Sysmex Europe GmbH, Norderstedt, Germany). PD-L1 expression on tumor cells was determined using a 22C3 assay for Autostainer Link 48 by Dako (Agilent Technologies, Santa Clara, CA), a negative PD-L1 status was defined as membranous staining on $< 1\%$ of viable tumor cells. Regardless of their statistical significance, ECOG and PD-L1 were included into the multivariate models for PFS/OS due to their well-established predictive implications, using the “augmented backward elimination package” in R.

3. Results

Baseline patient and tumor characteristics of the ICI monotherapy and ICI-CHT combination cohort for all patients and separately for men and women are shown in table 1.

	Mono-immunotherapy				Chemo-immunotherapy			
	All (n=228)	Male (n=136)	Female (n=92)	p	All (n=80)	Male (n=47)	Female (n=33)	p
Mean age (years; SE)	67.4 (0.71)	68.9 (1.0)	65.1 (1.0)	0.003	62.9 (1.1)	63.2 (1.3)	62.5 (1.8)	0.623
Age categories (n, %)								
<60 years	47 (20.6)	21 (15.4)	26 (29.3)	0.030	28 (35.0)	16 (34.0)	12 (36.4)	0.636
60-69 years	80 (35.1)	45 (33.1)	35 (38.0)		34 (42.5)	20 (42.6)	14 (42.4)	
70-79 years	25 (27.2)	53 (39.0)	25 (27.2)		17 (21.3)	11 (23.4)	6 (18.2)	
80+ years	6 (26.1)	17 (12.5)	6 (6.5)		1 (1.3)	0 (0.0)	1 (3.0)	
ECOG (n, %)								
0,1	172 (75.4)	107 (78.7)	65 (70.7)	0.167	68 (86.1)	38 (80.9)	30 (93.8)	0.104
≥2	56 (24.6)	29 (21.3)	27 (29.4)		11 (13.9)	9 (19.2)	2 (6.2)	
Mean pack years (SE)	45.1 (2.1)	50.9 (2.9)	36.5 (2.9)	<0.001	40.9 (3.0)	44.3 (3.7)	36.1 (4.8)	0.067
ICI substance (n, %)								
Nivolumab	90 (39.5)	52 (38.2)	38 (41.3)	0.897	-	-	-	NA
Pembrolizumab	105 (46.1)	64 (47.1)	41 (44.6)		77 (96.3)	45 (95.7)	32 (97)	
Atezolizumab	33 (14.5)	20 (14.7)	13 (14.1)		3 (3.8)	2 (4.3)	1 (3)	
Therapy line (n, %)								
1,2	136 (59.7)	110 (80.9)	72 (78.3)	0.629	77 (96.3)	45 (95.7)	32 (97)	NA
≥3	92 (40.3)	26 (21.7)	20 (21.7)		3 (3.8)	2 (4.3)	1 (3)	
Median number of ICI-CHT cycles (IQR)	-	-	-	-	4 (2)	4 (2)	4 (2)	0.962
Median number of ICI-monotherapy cycles (IQR)	4 (5)	4 (5)	4 (7)	0.343	3 (5.3)	3 (4)	2 (7)	0.761
Histological subtype (n, %)								
Adenocarcinoma	140 (62.2)	74 (54.8)	66 (73.3)	0.005	61 (77.2)	34 (73.9)	27 (81.8)	0.409
Squamous-cell carcinoma	85 (37.8)	61 (45.2)	24 (26.7)		18 (22.8)	12 (26.1)	6 (18.2)	
PD-L1 positive (n, %*)	137 (68.8)	84 (70.6)	53 (66.3)	0.517	41 (54.7)	23 (53.5)	18 (56.3)	0.812
PD-L1 expression (n, %**)								
n.a.	29 (12.7)	18 (13.2)	11 (12)	0.820	5 (6.3)	4 (8.5)	1 (3)	0.277
<1%	67 (29.4)	38 (27.9)	29 (31.5)		34 (42.5)	20 (42.6)	14 (42.4)	
1-49%	71 (31.1)	44 (32.4)	27 (29.3)		26 (32.5)	17 (36.2)	9 (27.3)	
≥50%	61 (26.8)	36 (26.5)	25 (27.2)		15 (18.6)	6 (12.8)	9 (27.3)	
Targetable genetic alteration (n, %)	18 (7.9)	6 (4.4)	12 (13.0)	0.018	6 (7.5)	2 (4.3)	4 (12.1)	0.189
Mean lymphocyte count (G/L; SE)	1.4 (0.1)	1.4 (0.1)	1.4 (0.1)	0.388	1.3 (0.1)	1.3 (0.1)	1.2 (0.1)	0.973
Mean C-reactive protein (mg/dL; SE)	3.5 (0.3)	3.5 (0.4)	3.4 (0.5)	0.261	3.1 (0.6)	2.6 (0.6)	3.7 (1.2)	0.788

Table 1. Baseline patient and tumor characteristics for all patients and according to

sex in the mono- and chemo-immunotherapy cohort. Results are presented as absolute number and percent within the respective group unless otherwise specified.

P values are for comparison between men and women.

*Percent of patients with PD-L1 status available.

**The numeric discrepancies between PD-L1 status and PD-L1 expression are due to patients with pathologically determined positive PD-L1 status but without exact quantification being reported or with further quantification being impossible.

SD=standard deviation, ECOG=Eastern Cooperative Oncology Group, ICI=Immune checkpoint inhibitor, CHT=chemotherapy, NA=not applicable, py=pack years, PD-L1=Programmed death-ligand 1

Kaplan-Meier analyses (figure 1) showed no significant sex difference, neither in the ICI monotherapy cohort (PFS: men 3M (3-5), women 3M (3-6), $p=0.273$; OS: men 10M (8-14), women 10M (6-14), $p=0.592$), nor in the CHT-ICI cohort (PFS: men 6M (5-10), women 5M (3-/-), $p=0.780$; OS: men 15M (10-NA), OS women: 10M (7-NA), $p=0.399$), respectively.




Figure 1. Kaplan-Meier curves for progression-free and overall survival in the mono- (a, b) and chemo-immunotherapy cohort (c, d) according to sex. Results are presented as months (95% confidence interval). CI=confidence interval, NA=not applicable

Uni- and multivariate predictors of PFS and OS for both therapy cohorts are presented in table 2.

	Univariate		Multivariate		Univariate		Multivariate	
	HR (95% CI)	p	HR (95% CI)	p	HR (95% CI)	p	HR (95% CI)	p
Mono-immunotherapy (n=228)	Progression-free survival				Overall survival			
Age (years)	0.99 (0.98-1.00)	0.543			0.99 (.098-1.00)	0.753		
Female vs. male	0.86 (0.65-1.15)	0.312			0.91 (0.66-1.25)	0.551		
ECOG (≥2 vs. 0,1)	1.51 (1.09-2.10)	0.014	1.56 (1.08-2.26)	0.017	1.89 (1.31-2.74)	<0.001	1.78 (1.17-2.72)	0.008
Therapy line (≥3 vs. 1,2)	1.50 (1.08-2.10)	0.002			1.45 (1.02-2.07)	0.040		
Targetable genetic alteration (yes vs. no)	1.64 (0.99-2.70)	0.060			1.87 (1.11-3.15)	0.020		
Lymphocyte count (G/L)	0.98 (0.85-1.13)	0.783			0.87 (0.72-1.06)	0.871		
Squamous-cell vs. adenocarcinoma	0.99 (0.74-1.32)	0.917			1.18 (0.86-1.62)	0.314		
Pack years (≥5 vs. <5)	0.93 (0.60-1.44)	0.731			1.03 (0.63-1.68)	0.917		
CRP (mg/dL)	1.05 (1.01-1.08)	0.005			1.08 (1.05-1.12)	<0.001	1.06 (1.02-1.10)	0.003
PD-L1 status (neg. vs. ≥1%)	1.56 (1.13-2.14)	0.006	1.51 (1.09-2.08)	0.013	1.22 (0.86-1.73)	0.268	1.21 (0.85-1.72)	0.303
Chemo-immunotherapy (n=80)	Progression-free survival				Overall survival			
Age (years)	1.00 (0.97-1.03)	0.884			1.01 (0.97-1.05)	0.691		
Female vs. male	1.09 (0.64-1.87)	0.747			1.32 (0.67-2.63)	0.423		
ECOG (≥2 vs. 0,1)	2.27 (1.13-4.56)	0.027	2.27 (1.07-4.80)	0.032	3.48 (1.59-7.63)	0.002	3.76 (1.50-9.42)	0.005
Targetable genetic alteration (yes vs. no)	2.02 (0.85-4.78)	0.110			1.96 (0.75-5.10)	0.171	2.85 (1.03-7.86)	0.043
Lymphocyte count (G/L)	1.08 (0.76-1.53)	0.688			0.84 (0.50-1.41)	0.500		
Squamous-cell vs. adenocarcinoma	1.55 (0.83-2.91)	0.171			1.59 (0.71-3.57)	0.265		
Pack years (≥5 vs. <5)	0.53 (0.27-1.07)	0.075			0.69 (0.26-1.79)	0.685		
CRP (mg/dL)	1.11 (1.06-1.18)	<0.001	1.11 (1.06-1.17)	<0.001	1.16 (1.10-1.22)	<0.001	1.13 (1.07-1.19)	<0.001
PD-L1 status (neg. vs. ≥1%)	1.48 (0.86-2.54)	0.155	1.76 (1.00-3.08)	0.049	1.43 (0.71-2.91)	0.319	1.57 (0.77-3.23)	0.219

Table 2. Uni- and multivariate analyses for progression-free- and overall survival for all patients in the mono-immunotherapy and chemo-immunotherapy cohort. Results are presented as hazard ratio (95% confidence interval), with a ratio >1 signifying an increased risk of progression/death or death, respectively. HR= hazard ratio, CI= Confidence Interval, ECOG= Eastern Cooperative Oncology Group, CRP= C-reactive protein, PD-L1= Programmed Death-Ligand 1

In the ICI monotherapy cohort, multivariate analyses showed ECOG and PD-L1 status as significant predictors of PFS, while OS was significantly influenced by ECOG and CRP. Chemo-immunotherapy-treated patients displayed a significant multivariate influence of ECOG, CRP and PD-L1 on PFS and of ECOG, presence of

a targetable genetic tumor alteration and CRP on OS. Sex did not play a significant role in these analyses; neither alone, nor in combination with any other variable evaluated.

Uni- and multivariate analyses for PFS and OS according to sex are shown in tables 3 and 4.

Progression-free survival	Univariate		Multivariate		Univariate		Multivariate	
	HR (95% CI)	p	HR (95% CI)	p	HR (95% CI)	p	HR (95% CI)	p
Mono-immunotherapy (n=228)	Male				Female			
Age (years)	0.99 (0.98-1.01)	0.860			0.99 (0.97-1.02)	0.351		
ECOG (≥2 vs. 0,1)	2.19 (1.39-3.45)	<0.001	1.90 (1.10-3.29)	0.021	1.16 (0.71-1.88)	0.553	1.27 (0.74-2.19)	0.384
Therapy line (≥3 vs. 1,2)	1.34 (0.86-2.10)	0.194			1.69 (1.01-2.52)	0.044		
Targetable genetic alteration (yes vs. no)	2.20 (0.88-5.46)	0.091			1.56 (0.83-2.92)	0.165		
Lymphocyte count (G/L)	1.03 (0.90-1.17)	0.660			0.83 (0.62-1.12)	0.228		
Squamous-cell vs. adenocarcinoma	0.99 (0.69-1.43)	0.954			0.92 (0.57-1.51)	0.752		
Pack years (≥5 vs. <5)	0.97 (0.45-2.09)	0.940			0.86 (0.49-1.50)	0.592		
CRP (mg/dL)	1.09 (1.04-1.13)	<0.001	1.06 (1.00-1.11)	0.037	1.01 (0.96-1.07)	0.696		
PD-L1 status (neg. vs. ≥1%)	1.93 (1.26-2.95)	0.002	2.04 (1.32-3.15)	0.001	1.29 (0.79-2.10)	0.316	1.26 (0.78-2.07)	0.344
Chemo-immunotherapy (n=80)	Male				Female			
Age (years)	1.01 (0.97-1.04)	0.717			0.99 (0.96-1.04)	0.936		
ECOG (≥2 vs. 0,1)	2.30 (1.02-5.23)	0.046	1.75 (0.72-.4.26)	0.217	6.06 (1.28-28.7)	0.023	5.18 (0.91-29.5)	0.064
Targetable genetic alteration (yes vs. no)	1.33 (0.32-5.61)	0.700			2.24 (0.74-6.84)	0.155		
Lymphocyte count (G/L)	0.97 (0.64-1.48)	0.896			1.60 (0.67-3.78)	0.288		
Squamous-cell vs. adenocarcinoma	2.68 (1.17-6.12)	0.019	4.00 (1.41-11.2)	0.009	1.04 (0.35-3.10)	0.938		
Pack years (≥5 vs. <5)	0.75 (0.29-1.96)	0.556			0.42 (0.15-1.19)	0.101		
CRP (mg/dL)	1.14 (1.04-1.25)	0.004			1.10 (1.04-1.17)	0.001	1.09 (1.02-1.16)	0.007
PD-L1 status (neg. vs. ≥1%)	1.45 (0.72-2.93)	0.297	1.45 (0.70-3.03)	0.321	1.62 (0.68-3.85)	0.274	1.59 (0.65-3.93)	0.311

Table 3. Uni- and multivariate analyses for progression-free survival in the mono- and chemo-immunotherapy cohort according to sex. Results are presented as hazard ratio (95% confidence interval), with a ratio >1 signifying an increased risk of progression/death. HR=hazard ratio, CI=Confidence Interval, ECOG=Eastern Cooperative Oncology Group, CRP=C-reactive protein, PD-L1=Programmed Death-Ligand 1

Overall survival	Univariate		Multivariate		Univariate		Multivariate	
	HR (95% CI)	p	HR (95% CI)	p	HR (95% CI)	p	HR (95% CI)	p
Mono-immunotherapy (n=228)	Male				Female			
Age (years)	1.00 (0.98-1.02)	0.783			0.99 (0.97-1.01)	0.345		
ECOG (≥2 vs. 0,1)	2.44 (1.44-4.12)	<0.001	1.78 (0.97-3.39)	0.063	1.64 (0.96-2.81)	0.072	1.90 (1.04-3.46)	0.037
Therapy line (≥3 vs. 1,2)	1.30 (0.81-2.09)	0.273			1.63 (0.94 -2.80)	0.090		
Targetable genetic alteration (yes vs. no)	1.97 (0.79-4.92)	0.145			1.87 (0.97-3.62)	0.060		
Lymphocyte count (G/L)	0.95 (0.78-1.14)	0.567			0.73 (0.51-1.04)	0.726		
Squamous-cell vs. adenocarcinoma	1.11 (0.74-1.66)	0.624			1.25 (0.74-2.10)	0.601		
Pack years (≥5 vs. <5)	0.83 (0.36-1.91)	0.666			1.10 (0.59-2.07)	0.764		
CRP (mg/dL)	1.11 (1.07-1.16)	<0.001	1.09 (1.03-1.14)	0.002	1.05 (0.99-1.10)	0.084		
PD-L1 status (neg. vs. ≥1%)	1.32 (0.83-2.09)	0.245	1.35 (0.84-2.16)	0.216	1.09 (0.64-1.88)	0.747	1.10 (0.64-1.90)	0.738
Chemo-immunotherapy (n=80)	Male				Female			
Age (years)	1.02 (0.96-1.07)	0.535			0.99 (0.95-1.05)	0.956		
ECOG (≥2 vs. 0,1)	4.89 (1.83-13.1)	0.002	5.58 (1.88-16.5)	0.002	3.74 (0.45-31.4)	0.225	1.26 (0.09-16.4)	0.860
Targetable genetic alteration (yes vs. no)	1.09 (0.14-8.30)	0.934			2.16 (0.67-6.68)	0.201		
Lymphocyte count (G/L)	0.62 (0.31-1.26)	0.187			1.63 (0.61-4.35)	0.329		
Squamous-cell vs. adenocarcinoma	1.93 (0.65-5.71)	0.237			1.23 (0.35-4.37)	0.751		
Pack years (≥5 vs. <5)	0.90 (0.21-3.96)	0.886			0.48 (0.13-1.80)	0.277		
CRP (mg/dL)	1.18 (1.08-1.70)	<0.001	1.19 (1.06-1.32)	0.002	1.13 (1.06-1.20)	<0.001	1.11 (1.03-1.19)	0.004
PD-L1 status (neg. vs. ≥1%)	1.27 (0.48-3.34)	0.634	2.78 (0.91-8.46)	0.072	1.78 (0.62-5.09)	0.282	1.39 (0.47-4.13)	0.553

Table 4. Uni- and multivariate analyses for overall survival in the mono- and chemo-immunotherapy cohort according to sex. Results are presented as hazard ratio (95% confidence interval), with a ratio >1 signifying an increased risk of death. HR=hazard ratio, CI=Confidence Interval, ECOG=Eastern Cooperative Oncology Group, CRP=C-reactive protein, PD-L1=Programmed Death-Ligand 1

Among women treated with ICI monotherapy, no significant predictor of PFS could be identified, while ECOG was significant for OS. Female patients in the ICI-CHT cohort showed a significant interaction of both PFS and OS with CRP. Men in the ICI monotherapy cohort had a significant impact of ECOG, CRP and PD-L1 status on PFS and of CRP on OS. Among male patients in the ICI-CHT cohort, squamous histology predicted reduced PFS, while ECOG and CRP proved significant for OS.

4. Discussion

Our data suggest that sex did not significantly influence outcomes in the reported cohorts of patients having received PD-1/PD-L1 directed ICI therapy either alone or in combination with platinum-based doublet CHT.

In the ICI monotherapy setting, multivariate models revealed ECOG and PD-L1 status as the main variables for PFS, while ECOG and CRP were most relevant for OS. Similarly, in the ICI-CHT combination cohort, ECOG, CRP and PD-L1 were the main determinants of PFS, and ECOG, presence of a targetable genetic alteration and CRP of OS. These findings largely resemble the current state of knowledge on predictive biomarkers for prediction of response to ICI therapy: Despite several years of biomarker research, PD-L1 expression, performance status and presence of a targetable genetic alteration like in EGFR or ALK are still the most common biomarkers routinely applied in daily clinical practice, knowing that their predictive power is limited.[20–22] In retrospective cohorts, elevated CRP has been demonstrated to be associated with inferior prognosis and may also positively correlate with PD-L1 expression.[23–25] Similarly, several other biomarkers related to the tumor microenvironment like tumor-infiltrating lymphocytes or more readily available clinical biomarkers like peripheral lymphocyte count or neutrophil to lymphocyte ratio have been suggested,[16,20,22] but are of only limited use and thus are not directly reflected in the therapeutic decision algorithms of current guidelines.[1]

Evidence from several meta-analyses suggests that men have more favorable responses to ICI monotherapies, while women have a comparably larger benefit on ICI-CHT combinations.[12,13] Although we did not detect significant differences between men and women concerning PFS and OS in either reported therapy group,

sex-specific uni- and multivariate analyses of predictive variables revealed interesting findings: Men had a significant impact of rather “traditional” factors like ECOG and PD-L1 as well as CRP and squamous histology for PFS and OS in the treatment cohorts. Women on the other hand showed no significant prognostic variable for ICI monotherapy PFS and only ECOG for OS in that cohort. For both ICI-CHT PFS and OS in female patients, CRP proved significant.

Imbalances in baseline patient characteristics may have influenced these findings: Both treatment cohorts included considerably more men than women probably mainly due to the higher incidence of lung cancer among men,[26] but still women have been reported less likely to receive ICI treatment for NSCLC in clinical practice.[27] This may in part be explained by the higher presence of targetable genetic alterations, especially in EGFR, among women.[1,21,27,28] Also in our study, the prevalence of these alterations in the ICI monotherapy group was significantly higher in women, but hazard ratios for progression (PFS) and death (OS) ranged from 1.09 to 2.24 without any significant uni-and multivariate findings in both sexes and treatment modalities. Another major difference between men and women concerning baseline characteristics was an overabundance of squamous-cell carcinomas among men, which was significant in the ICI monotherapy cohort and numerically evident in the ICI-CHT group. A higher incidence of squamous-cell carcinomas among men is well known,[26,29] and most major clinical trials on ICI monotherapy and ICI-CHT combinations except for KEYNOTE-024 reported better outcomes with non-squamous histology.[2–8] This may have influenced our reported sex-specific outcomes, as especially in ICI-CHT combination therapy, men with squamous histology had a higher HR for PFS and OS as compared to women (2.68 and 1.93 vs. 1.04 and 1.23, respectively). Similarly, smoking history significantly differed between men and women in the ICI monotherapy cohort but did not significantly impact clinical

outcomes in either sex. Recent research has shown that sex-differences in smoking habits and occupational exposure to other carcinogenic agents alone cannot fully explain the sex-specific alterations in lung cancer incidence and biology.[28] Sex hormone pathways, especially concerning β -estradiol are increasingly recognized as relevant factors in carcinogenesis and progression,[28] and may be an explanation for the comparatively higher incidence of lung cancer in female never smokers and in women <50 years.[28,30,31] In our reported ICI monotherapy cohort, age differed significantly between men and women, with an overabundance of women in the group <60 and of men in the group \geq 80 years, however age did not have significant implication of PFS and OS in further analyses.

Besides these mentioned sex differences on the demographic level, more profound variations in the pathophysiological mechanisms of anticancer immune response and tumor immune evasion contribute to the sex-specific response to ICI therapy.[12,13,15,32,33] Reportedly, women have stronger anti-tumor immune response patterns, which prompts NSCLC in female patients to develop more complex mechanisms of immune evasion, e.g. by enhanced expression of inhibitory immune checkpoint molecules leading to a higher degree of host T-cell dysfunction.[15] As a result, PD-1/PD-L1-directed monotherapy approaches may be less efficacious in women than in men. This also matches our observation that PD-L1 was shown to be a major predictor of PFS only in men receiving ICI monotherapy, although PD-L1 expression on tumor cells did not differ between sexes.

If tumor antigenicity however can be enhanced, e.g. by the application of CHT, women may derive a larger benefit from their stronger immune responses and enhanced immune cell infiltration into the tumor.[15,34] In this regard, like cytotoxic agents, radiotherapy can boost antitumor immune response pathways by inducing tumor antigen release and antigen presentation.[35] Retrospective analyses among

patients that had been treated with nivolumab in KEYNOTE-001 and had previously received radiotherapy showed that there was a non-significant numerical PFS and OS benefit favoring female patients.[36] In the PACIFIC trial evaluating durvalumab after chemoradiotherapy, both sexes displayed comparable PFS, but women achieved a distinctly better OS as compared to men.[37]

Naturally, our study and its results are limited by its retrospective, registry-based design. Still, it reflects two cohorts of patients treated in daily clinical practice at tertiary lung cancer centers and thus allows an insight into real life data that may unearth findings not evident in clinical trial settings. Although we regard the overall sample size of the ICI monotherapy cohort rather substantial, the ICI-CHT cohort as well as several subgroups in subsequent analyses were comparably small, which confines the significance of the statistical tests reported as well as the comparability between the two therapy cohorts. Also, reflecting the demographics of NSCLC incidence, more men than women were included in both reported cohorts, which may limit their comparability.

5. Conclusions

We conclude that although there was no evident sex difference in outcomes with either mono- or chemo-immunotherapy for advanced NSCLC, prognostic factors differed between men and women. These variations may be explained by sex-specific variations in host antitumor immune response and ICI therapy effects, as well as by differences in demographic and socioeconomic factors like smoking, comorbidities, and prevalence of targetable genetic tumor alterations. Our finding that known prognostic factors currently used in clinical practice seem to apply rather to male than to female patients urgently warrants further research in that field specifically for women.

Author Contributions: All authors have made significant contributions to this manuscript and meet the criteria for authorship as established by the International Committee of Medical Journal Editors, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising, or critically reviewing the article. All authors gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding: This research received no external funding.

Institutional Review Board Statement: This study was approved by the local ethics committees of Upper-Austria (EK Nr. 1139/2019). It was conducted in an entirely retrospective fashion, without an experimental approach or additional patient contact. Only patient data assessed in clinical routine were analyzed. Patient data were collected in an anonymized fashion and securely electronically stored in a way, that only the authors had access to the data.

Informed Consent Statement: The need for patients' written informed consent was waived according to the institutional ethics committee's regulations for non-interventional retrospective studies.

Data Availability Statement: According to the terms imposed by the ethics committee, the full datasets analyzed during the current study cannot be made publicly available, as they contain possibly identifiable patient data. Upon reasonable request to the authors and if approved as an amendment by the responsible local ethics committee, selected anonymized data can however be shared.

Acknowledgements: None.

Conflicts of interest: DL has served as consultant/advisor to Roche and Merck Sharp & Dohme and received travel/accommodation funding from Roche and Merck Sharp & Dohme. FH has received travel/accommodation funding from Bristol-Myers Squibb, Roche and Merck Sharp & Dohme. GR has served as consultant/advisor to Roche, has received speakers' honoraria from Bristol-Myers Squibb and Roche and has received travel/accommodation and research funding from Roche. AH has received travel/accommodation funding from Roche. RW has received speakers' honoraria and travel/accommodation funding from and served as consultant/advisor to Roche, Merck Sharp & Dohme and Bristol-Myers Squibb. EB has received speakers' honoraria from and served as consultant/advisor to Roche, Merck Sharp & Dohme, and Bristol-Myers Squibb; he has received travel/accommodation funding from Roche and Merck Sharp & Dohme. RG has received speakers' honoraria and research funding from Roche, Merck Sharp & Dohme and Bristol-Myers Squibb, he has served as consultant/advisor to Roche and Bristol-Myers Squibb and has received travel/accommodation funding from Roche. BL has received speakers' honoraria from and has served as consultant/advisor to Roche, Merck Sharp & Dohme and Bristol-Myers Squibb. AB and BK declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.

References

1. Planchard, D.; Popat, S.; Kerr, K.; Novello, S.; Smit, E.F.; Faivre-Finn, C.; Mok, T.S.; Reck, M.; Van Schil, P.E.; Hellmann, M.D.; et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* **2018**, *29*, iv192–iv237, doi:10.1093/annonc/mdy275.
2. Borghaei, H.; Paz-Ares, L.; Horn, L.; Spigel, D.R.; Steins, M.; Ready, N.E.; Chow, L.Q.; Vokes, E.E.; Felip, E.; Holgado, E.; et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer. *N. Engl. J. Med.* **2015**, *373*, 1627–1639, doi:10.1056/NEJMoa1507643.
3. Brahmer, J.; Reckamp, K.L.; Baas, P.; Crinò, L.; Eberhardt, W.E.E.; Poddubskaya, E.; Antonia, S.; Pluzanski, A.; Vokes, E.E.; Holgado, E.; et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer. *N. Engl. J. Med.* **2015**, *373*, 123–135, doi:10.1056/NEJMoa1504627.
4. Herbst, R.S.; Baas, P.; Kim, D.-W.; Felip, E.; Pérez-Gracia, J.L.; Han, J.-Y.; Molina, J.; Kim, J.-H.; Arvis, C.D.; Ahn, M.-J.; et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet* **2016**, *387*, 1540–1550, doi:10.1016/S0140-6736(15)01281-7.
5. Reck, M.; Rodríguez-Abreu, D.; Robinson, A.G.; Hui, R.; Csőszi, T.; Fülöp, A.; Gottfried, M.; Peled, N.; Tafreshi, A.; Cuffe, S.; et al. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. *N. Engl. J. Med.* **2016**, *375*, 1823–1833, doi:10.1056/NEJMoa1606774.
6. Rittmeyer, A.; Barlesi, F.; Waterkamp, D.; Park, K.; Ciardiello, F.; von Pawel, J.;

- Gadgeel, S.M.; Hida, T.; Kowalski, D.M.; Dols, M.C.; et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. *Lancet* **2017**, *389*, 255–265, doi:10.1016/S0140-6736(16)32517-X.
7. Gandhi, L.; Rodríguez-Abreu, D.; Gadgeel, S.; Esteban, E.; Felip, E.; De Angelis, F.; Domine, M.; Clingan, P.; Hochmair, M.J.; Powell, S.F.; et al. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer. *N. Engl. J. Med.* **2018**, *378*, 2078–2092, doi:10.1056/NEJMoa1801005.
 8. Paz-Ares, L.; Luft, A.; Vicente, D.; Tafreshi, A.; Gümüş, M.; Mazières, J.; Hermes, B.; Çay Şenler, F.; Csőszi, T.; Fülöp, A.; et al. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer. *N. Engl. J. Med.* **2018**, *379*, 2040–2051, doi:10.1056/NEJMoa1810865.
 9. Socinski, M.A.; Jotte, R.M.; Cappuzzo, F.; Orlandi, F.; Stroyakovskiy, D.; Nogami, N.; Rodríguez-Abreu, D.; Moro-Sibilot, D.; Thomas, C.A.; Barlesi, F.; et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. *N. Engl. J. Med.* **2018**, *378*, 2288–2301, doi:10.1056/NEJMoa1716948.
 10. Paz-Ares, L.; Ciuleanu, T.-E.; Cobo, M.; Schenker, M.; Zurawski, B.; Menezes, J.; Richardet, E.; Bennouna, J.; Felip, E.; Juan-Vidal, O.; et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. *Lancet Oncol.* **2021**, *22*, 198–211, doi:10.1016/S1470-2045(20)30641-0.

11. Hellmann, M.D.; Ciuleanu, T.-E.; Pluzanski, A.; Lee, J.S.; Otterson, G.A.; Audigier-Valette, C.; Minenza, E.; Linardou, H.; Burgers, S.; Salman, P.; et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. *N. Engl. J. Med.* **2018**, *378*, 2093–2104, doi:10.1056/NEJMoa1801946.
12. Conforti, F.; Pala, L.; Bagnardi, V.; De Pas, T.; Martinetti, M.; Viale, G.; Gelber, R.D.; Goldhirsch, A. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis. *Lancet Oncol.* **2018**, *19*, 737–746, doi:10.1016/S1470-2045(18)30261-4.
13. Wallis, C.J.D.; Butaney, M.; Satkunasivam, R.; Freedland, S.J.; Patel, S.P.; Hamid, O.; Pal, S.K.; Klaassen, Z. Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers. *JAMA Oncol.* **2019**, *5*, 529, doi:10.1001/jamaoncol.2018.5904.
14. Conforti, F.; Pala, L.; Bagnardi, V.; Viale, G.; De Pas, T.; Pagan, E.; Pennacchioli, E.; Cocorocchio, E.; Ferrucci, P.F.; De Marinis, F.; et al. Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis. *JNCI J. Natl. Cancer Inst.* **2019**, *111*, 772–781, doi:10.1093/jnci/djz094.
15. Conforti, F.; Pala, L.; Pagan, E.; Bagnardi, V.; De Pas, T.; Queirolo, P.; Pennacchioli, E.; Catania, C.; Cocorocchio, E.; Ferrucci, P.F.; et al. Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. *Clin. Cancer Res.* **2021**, *27*, 4311–4324, doi:10.1158/1078-0432.CCR-21-0136.
16. Huemer; Lang; Westphal; Gampenrieder; Hutarew; Weiss; Hackl; Lamprecht;

- Rinnerthaler; Greil Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade. *J. Clin. Med.* **2019**, *8*, 1014, doi:10.3390/jcm8071014.
17. Lang, D.; Horner, A.; Brehm, E.; Akbari, K.; Hergan, B.; Langer, K.; Asel, C.; Scala, M.; Kaiser, B.; Lamprecht, B. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC—A retrospective cohort study. *Lung Cancer* **2019**, *134*, 59–65, doi:10.1016/j.lungcan.2019.05.033.
 18. Lang, D.; Huemer, F.; Rinnerthaler, G.; Horner, A.; Wass, R.; Brehm, E.; Akbari, K.; Granitz, M.; Hutarew, G.; Kaiser, B.; et al. Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study. *Target. Oncol.* **2019**, doi:10.1007/s11523-019-00679-9.
 19. Chansky, K.; Detterbeck, F.C.; Nicholson, A.G.; Rusch, V.W.; Vallières, E.; Groome, P.; Kennedy, C.; Krasnik, M.; Peake, M.; Shemanski, L.; et al. The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer. *J. Thorac. Oncol.* **2017**, *12*, 1109–1121, doi:10.1016/j.jtho.2017.04.011.
 20. Cyriac, G.; Gandhi, L. Emerging biomarkers for immune checkpoint inhibition in lung cancer. *Semin. Cancer Biol.* **2018**, *52*, 269–277, doi:10.1016/j.semcancer.2018.05.006.
 21. Lee, C.K.; Man, J.; Lord, S.; Cooper, W.; Links, M.; GebSKI, V.; Herbst, R.S.;

- Gralla, R.J.; Mok, T.; Yang, J.C.-H. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma. *JAMA Oncol.* **2018**, *4*, 210, doi:10.1001/jamaoncol.2017.4427.
22. Prelaj, A.; Tay, R.; Ferrara, R.; Chaput, N.; Besse, B.; Califano, R. Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer. *Eur. J. Cancer* **2019**, *106*, 144–159, doi:10.1016/j.ejca.2018.11.002.
23. Akamine, T.; Takada, K.; Toyokawa, G.; Kinoshita, F.; Matsubara, T.; Kozuma, Y.; Haratake, N.; Takamori, S.; Hirai, F.; Tagawa, T.; et al. Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers. *Surg. Oncol.* **2018**, *27*, 88–94, doi:10.1016/j.suronc.2018.01.002.
24. Riedl, J.M.; Barth, D.A.; Brueckl, W.M.; Zeitler, G.; Foris, V.; Mollnar, S.; Stotz, M.; Rossmann, C.H.; Terbuch, A.; Balic, M.; et al. C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study. *Cancers (Basel)*. **2020**, *12*, 2319, doi:10.3390/cancers12082319.
25. Adachi, Y.; Tamiya, A.; Taniguchi, Y.; Enomoto, T.; Azuma, K.; Kouno, S.; Inagaki, Y.; Saijo, N.; Okishio, K.; Atagi, S. Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status. *Cancer Med.* **2020**, *9*, 1383–1391, doi:10.1002/cam4.2807.
26. Hackl, M.; Ihle, P. *Krebserkrankungen in Österreich 2020*; Statistik Austria, Ed.; Statistik Austria: Vienna, 2020; ISBN 978-3-903264-40-3.

27. O'Connor, J.M.; Seidl-Rathkopf, K.; Torres, A.Z.; You, P.; Carson, K.R.; Ross, J.S.; Gross, C.P. Disparities in the Use of Programmed Death 1 Immune Checkpoint Inhibitors. *Oncologist* **2018**, *23*, 1388–1390, doi:10.1634/theoncologist.2017-0673.
28. Smida, T.; Bruno, T.C.; Stabile, L.P. Influence of Estrogen on the NSCLC Microenvironment: A Comprehensive Picture and Clinical Implications. *Front. Oncol.* **2020**, *10*, doi:10.3389/fonc.2020.00137.
29. Socinski, M.A.; Obasaju, C.; Gandara, D.; Hirsch, F.R.; Bonomi, P.; Bunn, P.; Kim, E.S.; Langer, C.J.; Natale, R.B.; Novello, S.; et al. Clinicopathologic Features of Advanced Squamous NSCLC. *J. Thorac. Oncol.* **2016**, *11*, 1411–1422, doi:10.1016/j.jtho.2016.05.024.
30. Wakelee, H.A.; Chang, E.T.; Gomez, S.L.; Keegan, T.H.; Feskanich, D.; Clarke, C.A.; Holmberg, L.; Yong, L.C.; Kolonel, L.N.; Gould, M.K.; et al. Lung Cancer Incidence in Never Smokers. *J. Clin. Oncol.* **2007**, *25*, 472–478, doi:10.1200/JCO.2006.07.2983.
31. Jemal, A.; Miller, K.D.; Ma, J.; Siegel, R.L.; Fedewa, S.A.; Islami, F.; Devesa, S.S.; Thun, M.J. Higher Lung Cancer Incidence in Young Women Than Young Men in the United States. *N. Engl. J. Med.* **2018**, *378*, 1999–2009, doi:10.1056/NEJMoa1715907.
32. Klein, S.L.; Flanagan, K.L. Sex differences in immune responses. *Nat. Rev. Immunol.* **2016**, *16*, 626–638, doi:10.1038/nri.2016.90.
33. Lotter, H.; Altfeld, M. Sex differences in immunity. *Semin. Immunopathol.* **2019**, *41*, 133–135, doi:10.1007/s00281-018-00728-x.

34. Wang, S.; Cowley, L.A.; Liu, X.-S. Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy. *Molecules* **2019**, *24*, 3214, doi:10.3390/molecules24183214.
35. Hendriks, L.E.L.; Menis, J.; De Ruyscher, D.K.M.; Reck, M. Combination of Immunotherapy and Radiotherapy—The Next Magic Step in the Management of Lung Cancer? *J. Thorac. Oncol.* **2020**, *15*, 166–169, doi:10.1016/j.jtho.2019.12.106.
36. Shaverdian, N.; Lisberg, A.E.; Bornazyan, K.; Veruttipong, D.; Goldman, J.W.; Formenti, S.C.; Garon, E.B.; Lee, P. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. *Lancet Oncol.* **2017**, *18*, 895–903, doi:10.1016/S1470-2045(17)30380-7.
37. Antonia, S.J.; Villegas, A.; Daniel, D.; Vicente, D.; Murakami, S.; Hui, R.; Yokoi, T.; Chiappori, A.; Lee, K.H.; de Wit, M.; et al. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. *N. Engl. J. Med.* **2017**, *377*, 1919–1929, doi:10.1056/NEJMoa1709937.